Immatics Beats 2025 Revenue Estimates, Advances Key Clinical Programs
summarizeSummary
Immatics N.V. reported stronger-than-expected financial results for 2025, with collaboration revenue of EUR 48.27 million significantly beating analyst consensus of EUR 37.82 million. The company also surpassed estimates for net income and operating income. Alongside these financial beats, Immatics provided positive updates on its clinical pipeline, including an anticipated Biologics License Application (BLA) submission for anzu-cel in the first half of 2027 and plans for a new IMA402/IMA401 combination trial in lung cancer in 2026. These results and pipeline advancements signal robust operational execution and progress towards key regulatory and clinical milestones, which are critical for a biopharmaceutical firm. Traders will be watching for the upcoming IMA203CD8 Phase 1a data in ovarian cancer in 1H 2026 and further updates on the anzu-cel BLA timeline.
At the time of this announcement, IMTX was trading at $10.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $3.30 to $12.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.